Holen Sie sich die Stockscreener-App
42.32
3.49%
1.94
Schlusskurs vom Vortag:
$40.38
Offen:
$41.23
24-Stunden-Volumen:
144.39K
Relative Volume:
0.19
Marktkapitalisierung:
$2.97B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-170.73M
KGV:
-15.72
EPS:
-2.6921
Netto-Cashflow:
$-159.70M
1W Leistung:
-12.57%
1M Leistung:
-21.36%
6M Leistung:
-26.04%
1J Leistung:
+96.66%
1-Tages-Spanne:
$40.49
$42.01
1-Wochen-Bereich:
$40.26
$48.25
52-Wochen-Spanne:
$20.04
$94.90
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
Firmenname
Structure Therapeutics Inc Adr
Sektor
Branche
Telefon
(650) 457-1978
Adresse
601 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO
Compare GPCR vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GPCR
Structure Therapeutics Inc Adr
|
41.67 | 2.88B | 0 | -170.73M | -159.70M | -2.6921 |
VRTX
Vertex Pharmaceuticals Inc
|
520.83 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.47 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
998.39 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.04 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.72 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-03-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-05-02 | Eingeleitet | Citigroup | Buy |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-05-21 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-07-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-28 | Eingeleitet | Guggenheim | Buy |
| 2023-02-28 | Eingeleitet | Jefferies | Buy |
| 2023-02-28 | Eingeleitet | SVB Securities | Outperform |
Alle ansehen
Structure Therapeutics Inc Adr Aktie (GPCR) Neueste Nachrichten
Structure Therapeutics stock price target maintained at $70 by H.C. Wainwright - Investing.com Canada
Citizens reiterates Structure Therapeutics stock rating on trial data By Investing.com - Investing.com Canada
Jefferies raises Structure Therapeutics stock target on amylin data By Investing.com - Investing.com Canada
Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study - Zacks Investment Research
Structure Therapeutics Reports Positive ACCG-2671 Early Trial Results - TipRanks
Oral obesity drug shows double-digit weight loss as Structure Therapeutics (NASDAQ: GPCR) advances Phase 3 trials - Stock Titan
A weight-loss pill cut body weight 16.2% in 72 weeks - Stock Titan
Analysts Conflicted on These Healthcare Names: Kymera Therapeutics (KYMR) and vTv Therapeutics (VTVT) - The Globe and Mail
Morgan Stanley’s conference is one of three Structure Therapeutics plans to join in September - Stock Titan
Structure Therapeutics (GPCR) CSO sells 5,939 ADSs under preset plan - Stock Titan
(GPCR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now? - Yahoo Finance
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX) - The Globe and Mail
Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s? - TradingView
Handelsbanken Fonder AB Purchases Shares of 19,400 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (GPCR) exec sells 3,939 ADSs under plan - Stock Titan
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's? - TradingView
Structure Therapeutics IncADR (GPCR) News, Articles, Events & Latest Updates - Stocktwits
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock? - TradingView
Structure Therapeutics (NASDAQ:GPCR) Rating Increased to Sell at Wall Street Zen - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxis Oncology (PYXS) - The Globe and Mail
Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge? - TradingView
LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1? - TradingView
Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock? - TradingView
Structure Therapeutics Slumps As Analysts Turn Sharply Bearish - TipRanks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR) - The Globe and Mail
HC Wainwright Has Bearish Forecast for GPCR Q3 Earnings - MarketBeat
Pacira Pharmaceuticals (PCRX) Receives a Sell from J.P. Morgan - The Globe and Mail
Price-Driven Insight from (GPCR) for Rule-Based Strategy - Stock Traders Daily
Renaissance Technologies LLC Sells 59,400 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPS - MarketBeat
Piper Sandler Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (CTMX), Cytokinetics (CYTK) and Scholar Rock Holding (SRRK) - The Globe and Mail
GPCR SWOT Analysis: Financial Challenges and Opportunities Revea - GuruFocus
Citizens lowers Structure Therapeutics stock price target on GLP agonist By Investing.com - Investing.com South Africa
Citigroup Cuts Structure Therapeutics (NASDAQ:GPCR) Price Target to $97.00 - MarketBeat
Structure Therapeutics (GPCR) awards options and RSUs to its CCO - Stock Titan
Structure Therapeutics Inc. (GPCR) files initial Form 3 for CCO - Stock Titan
Structure Therapeutics (NASDAQ:GPCR) Given New $110.00 Price Target at Citizens Jmp - MarketBeat
Citizens lowers Structure Therapeutics stock price target on GLP agonist - Investing.com
Structure Therapeutics Chief Commercial Officer John Joseph Berrios files initial beneficial ownership statement - Bitget
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Buy Rating Reiterated on Structure Therapeutics as Obesity Pipeline Advances; $104 Price Target Maintained - TipRanks
Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights - The Manila Times
FMR LLC discloses major 13.2% GPCR stake in Structure Therapeutics Inc (GPCR) - Stock Titan
Structure Therapeutics (GPCR) CSO sells 3,939 ADS after option exercise - Stock Titan
Structure Therapeutics Inc. (GPCR) Stock Analysis: Potential Upside of 116.78% Amid Promising Clinical Trials - DirectorsTalk Interviews
Avidity Partners Management LP Buys Shares of 30,000 Structure Therapeutics Inc. Sponsored ADR $GPCR - MarketBeat
Structure Therapeutics (NASDAQ:GPCR) Upgraded at Wall Street Zen - MarketBeat
Finanzdaten der Structure Therapeutics Inc Adr-Aktie (GPCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):